Cover Image
市場調查報告書

B型流感病毒感染:開發中產品分析

Influenzavirus B Infections - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 484630
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
Back to Top
B型流感病毒感染:開發中產品分析 Influenzavirus B Infections - Pipeline Review, H1 2018
出版日期: 2018年03月13日 內容資訊: 英文 129 Pages
簡介

B型流感是零星發生並具有發射性傳染趨勢的流感病毒亞型。症候有鼻涕,咽喉炎,肌肉痛,不舒服,淚眼,身體疼痛,食慾衰退,衰弱等。治療有使用處方抗病毒藥物,止痛藥,退燒藥等。

本報告提供全球各國治療B型流感病毒感染所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介+

  • 調查範圍

B型流感病毒感染;概要

B型流感病毒感染 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Altravax Inc
  • Amarillo Biosciences Inc
  • Aphios Corp
  • BioClonetics Immunotherapeutics Inc
  • ContraFect Corp
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Ilyang Pharmaceutical Co Ltd
  • Kineta Inc
  • Medicago Inc
  • MedImmune LLC
  • Mucosis BV
  • Novavax Inc
  • Protein Sciences Corp
  • Romark Laboratories LC
  • Sanofi Pasteur SA
  • 鹽野義製藥
  • SK Chemicals Co Ltd
  • 富山化學工業
  • TSRL Inc
  • Vaxart Inc
  • Vectura Group Plc
  • Zydus Cadila Healthcare Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10248IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2018, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 16, 3, 4, 1, 10 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Influenzavirus B Infections - Overview
  • Influenzavirus B Infections - Therapeutics Development
  • Influenzavirus B Infections - Therapeutics Assessment
  • Influenzavirus B Infections - Companies Involved in Therapeutics Development
  • Influenzavirus B Infections - Drug Profiles
  • Influenzavirus B Infections - Dormant Projects
  • Influenzavirus B Infections - Discontinued Products
  • Influenzavirus B Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Influenzavirus B Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Influenzavirus B Infections - Pipeline by AbbVie Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Adimmune Corp, H1 2018
  • Influenzavirus B Infections - Pipeline by Altravax Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Amarillo Biosciences Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Aphios Corp, H1 2018
  • Influenzavirus B Infections - Pipeline by AusBio Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Biotron Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by Cadila Healthcare Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by ContraFect Corp, H1 2018
  • Influenzavirus B Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by GC Pharma, H1 2018
  • Influenzavirus B Infections - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Johnson & Johnson, H1 2018
  • Influenzavirus B Infections - Pipeline by Kineta Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Medicago Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by MedImmune LLC, H1 2018
  • Influenzavirus B Infections - Pipeline by Mucosis BV (Inactive), H1 2018
  • Influenzavirus B Infections - Pipeline by Novavax Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H1 2018
  • Influenzavirus B Infections - Pipeline by Sanofi, H1 2018
  • Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H1 2018
  • Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by Sinovac Biotech Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by SK Chemicals Co Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by Toyama Chemical Co Ltd, H1 2018
  • Influenzavirus B Infections - Pipeline by TSRL Inc, H1 2018
  • Influenzavirus B Infections - Pipeline by Vaxart Inc, H1 2018
  • Influenzavirus B Infections - Dormant Projects, H1 2018
  • Influenzavirus B Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Influenzavirus B Infections - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Influenzavirus B Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top